How do you sequence HER2-therapy in HER2+ biliary tract cancer with the positive results of tucatinib + trastuzumab and zanidatamab in phase 2 studies?
Answer from: Medical Oncologist at Academic Institution
The significance of targeting HER2 in patients with HER2 amplified biliary tract cancers was showcased in two studies at ASCO 2023. HERIZON-BTC (abstract 4008) reported a response rate of 41% and mDOR of 12.9 months for zanidatamab, a bispecific antibody targeting HER2. A basket study testing the ef...
Sign in or Register to read more